Following the failure of the recent solanezumab trial the question now is where does Alzheimer’s research go from here? We have brought together four top experts to discuss:
Is the solanezumab trial a complete failure? Can we learn anything from it?
Is this the end for the amyloid hypothesis? Could we be going about this all wrong? Is Tau the answer?
What other drugs are in the pipeline? Do the solanezumab results lower our hopes for their success?
Are there other non-drug therapies on the horizon that might offer success?
Will we not progress until we get better at detecting and diagnosing this disease?
Do we think we will ever find a treatment? Is our only hope to reduce lifestyle risks as much as possible?
Prof Nick Fox, Professor of Neurology, MRC Senior Clinical Fellow, Institute of Neurology, UCL
Prof John Hardy, Professor of Neuroscience, UCL
Dr David Reynolds, Chief Scientific Officer, Alzheimer’s Research UK
Dr Tara Spires-Jones, Interim Director, Centre for Cognitive and Neural Systems, University of Edinburgh